USANA Health Sciences stock: Q3 sales fall, outlook cut
Published on 11/17/2026 at 03:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUSANA resets its 2026 outlook
- Third-quarter net sales declined to USD 205.9 million, while the net loss narrowed year over year.
- Hiya subscriber growth and stronger Core Nutritional margins partly offset weaker customer numbers and Rise Wellness sales.
- The company ended the quarter with USD 179 million in cash and no debt.
USANA Health Sciences reported lower third-quarter sales and reduced its 2026 outlook on November 3, 2026. In its earnings release, the company said net sales fell 3.6 percent year over year to USD 205.9 million for the quarter ended October 3.
Sales pressure weighs on guidance
USANA posted a net loss attributable to the company of USD 5.6 million, compared with a USD 6.5 million loss a year earlier. Diluted loss per share improved to USD 0.30 from USD 0.36, while adjusted diluted loss per share narrowed to USD 0.11 from USD 0.15.
Adjusted EBITDA declined to USD 12.1 million from USD 13.8 million. The company now expects 2026 consolidated net sales to approach USD 900 million and adjusted EBITDA to reach USD 77 million, compared with previous estimates of USD 910 million and USD 80.5 million, respectively.
Hiya growth offsets weaker segments
Hiya Health generated USD 31.5 million in quarterly sales, up 2.3 percent from a year earlier. Active monthly subscribers increased 18 percent sequentially to 195,500, supported by higher customer acquisition investment and expanding sales through Target and Amazon.
Core Nutritional sales fell 3.1 percent to USD 170.7 million, while active customers declined 8 percent to 356,000. Rise sales dropped 44.8 percent to USD 3.6 million. Management said rebuilding the Core Nutritional customer base remains a central growth priority.
Cash position supports investment
USANA generated USD 35.7 million in free cash flow during the first nine months of 2026. Inventory declined 13 percent from year-end 2025, and the company finished the quarter with USD 178.9 million in cash and no debt. Management expects continued sequential progress from Hiya in the fourth quarter while investing in customer acquisition.
USANA's business and market position
USANA develops and manufactures nutritional supplements, functional foods and personal care products sold directly to Brand Partners and Preferred Customers across 25 global markets. The Salt Lake City, Utah-based company also owns a controlling interest in Hiya Health Products, a children's health and wellness business, and owns Rise Wellness.
Its portfolio spans direct selling, subscription-based children's nutrition and emerging retail health products. The company is therefore combining an established direct-sales operation with newer omnichannel businesses as it works to rebuild customer growth.
USANA Health Sciences at a glance
- Company: USANA Health Sciences, Inc.
- Confirmed ISIN: US90328M1071
- Ticker: USNA
- Home exchange: New York Stock Exchange
- Quarter ended: October 3, 2026
- Headquarters: Salt Lake City, Utah, United States
The company operates in the healthcare and wellness market alongside the broader U.S. equity market, tracked through the S&P 500.
